Since 2021, following the launch of the European Plan to Combat Cancer, the European Union (EU) is investing heavily in the fight against cancer. This plan sets out a new EU approach to cancer prevention, treatment and care. In particular, it proposes ten flagship initiatives and multiple measures to address all stages of the disease, from prevention to quality of life for cancer patients and survivors, focusing on those measures where the EU can add most value. To this end, it is funding numerous European initiatives aimed at the fight against cancer, within the EU4Health work program.
In this context, since 2022 the Medical Oncology group HUMV – IDIVAL has been expanding its participation in various joint actions in this area. Firstly, it participates in the joint action eCAN (Joint Action on strengthening eHealth including telemedicine and telemonitoring for health care systems for cancer prevention and care) (2022-2024), whose overall objective is to evaluate the benefits of teleconsultation and telemonitoring on the quality of life of patients with different types of cancer. Among the activities developed in this initiative, the Medical Oncology Service of HUMV participated in two pilot studies in patients with newly diagnosed breast cancer and in patients with advanced cancer, with the aim of evaluating the possible benefits of a tele-rehabilitation program or remote psycho-oncology support, respectively, with very satisfactory results for both patients and healthcare staff involved. This team also participates in two closely linked joint actions: JANE (Joint Action on Networks of Expertise) (2022-2024), whose ultimate aim is to create networks of experts in different areas of cancer, such as personalized primary prevention, survivorship, palliative care, omic technologies, high-tech medical resources, poor prognosis or complex cancer; and CraNE (Network of Comprehensive Cancer Centres: Preparatory activities on creation of National Comprehensive Cancer Centres and EU Networking) (2022-2024), whose objective is to establish the necessary pre-conditions to create a network of comprehensive cancer centers (CCC) in Europe. Likewise, since 2024 this team participates in the joint action EUCanScreen (Implementation of cancer screening programmes) (2024-2028) where the Digestive team of HUMV/IDIVAL also collaborates, and whose objective is to guarantee the sustainability of the implementation of high quality screening tests for breast, cervical and colorectal cancer, as well as the implementation of the recently recommended screening programs for lung, prostate and gastric cancer, thus facilitating the reduction of the cancer burden and achieving equity throughout the EU.
Finally, from late 2024/early 2025, the HUMV/IDIVAL Medical Oncology Service, and in collaboration with other HUMV services, including the Hematology Service, will participate in two new joint actions: EUnetCCC and JANE-2. EUnetCCC (The European Comprehensive Cancer Centre Network) is a continuation of the current CraNE joint action, through which the aim is for numerous centers in Europe, including HUMV, to be accredited as CCCs. This will provide cancer patients with greater access to early detection programs, screening, diagnosis, treatment, innovative strategies, research and training of oncology staff, in line with the objectives of the European Cancer Plan. JANE-2 (Joint Action on Networks of Expertise on Cancer), on the other hand, is a European initiative which, based on previous work carried out in the context of its predecessor joint action (JANE), aims to create and implement seven networks of experts in different areas of cancer: cancer with a poor prognosis or complex, palliative care, survivorship, personalized primary/secondary prevention, omics technologies, high-tech medical resources, and adolescents and young adults with cancer.
The results derived from the participation of the team in all these European initiatives will bring great benefits for cancer patients, resulting in significant improvements in the management of their disease and in their quality of life. Furthermore, it is of great strategic interest for IDIVAL, HUMV, the Cantabrian Health Service and, in general, for the National Health System, because of its contribution to the objective of trying to position and consolidate our center and health system as a national and international reference in the field of oncology, as well as for the potential health and socioeconomic benefits associated with the development of these projects.
Cover photo: HUMV Medical Oncology Group – IDIVAL
The Medical Oncology Service of the Marqués de Valdecilla University Hospital participates in numerous European initiatives within the EU4Health program. Since 2021, following the launch of the European Plan to Combat Cancer, the European Union (EU) is investing heavily in the fight against cancer. This plan sets out a new EU approach to cancer prevention, […]
The research article titled “Sensitization symptoms are associated with psychological and cognitive variables in COVID-19 survivors exhibiting post-COVID pain,” carried out by researchers of the IDIVAL nursing group, in collaboration with the Pneumology Service of the Marqués de Valdecilla University Hospital (HUMV) Paula Parás Bravo, Manuel Herrero Montes and Diego Ferrer Pargada, focuses on post-COVID pain, a condition affecting a significant proportion of SARS-CoV-2 survivors.
The research reveals that up to 60% of COVID-19 survivors may develop long-term symptoms known as persistent COVID, with a high percentage experiencing chronic musculoskeletal pain. This type of pain, characterized as nociplastic, is not only associated with high pain intensity but also with psychological and cognitive symptoms such as anxiety, depression, and catastrophizing.
The study’s results show that self-reported sensitization symptoms are closely related to pain intensity, anxiety and depression levels, as well as catastrophizing and kinesiophobia in COVID-19 survivors who were hospitalized. Regression analysis indicates that 60.2% of the variance in Central Sensitization Inventory (CSI) scores can be explained by anxiety levels and pain intensity, suggesting that post-COVID pain exhibits characteristics of a nociplastic condition.
The patients were drawn from their specific post-COVID consultation, where more than 500 people who had suffered severe COVID infections and other patients, who despite initial mild involvement, presented later limiting symptomatology, were reviewed.
The project, funded by the Next-Val 2021 call from IDIVAL, has been crucial for better understanding the mechanisms behind post-COVID pain and guiding personalized treatments for survivors. This research not only highlights the importance of integrating psychological and cognitive variables into pain management but also underscores the need for a more comprehensive approach to address the complex symptoms associated with persistent COVID.
Thanks to the results obtained, the article has seen very high interaction in citations by other researchers who have referenced the work of IDIVAL’s nursing research group.
For more details on this research, you are invited to read the full article: https://doi.org/10.1111/papr.13146
Cover Photo: IDIVAL Nursing Research Group
Published in June 2022, the article has been recognized by Wiley as one of the ten most cited during 2022 and 2023 in the journal PAIN Practice The research article titled “Sensitization symptoms are associated with psychological and cognitive variables in COVID-19 survivors exhibiting post-COVID pain,” carried out by researchers of the IDIVAL nursing group, […]
The ambitious biomedical research project Cohorte Cantabria has today reached 40,000 participants, approaching its goal of 50,000 volunteers. The great reception of this initiative by the Cantabrian population reflects the commitment of our citizens to improve public health through research. The study has become so important that it has been presented to His Majesty King Felipe VI and on June 27th the Governing Council declared it a strategic action at regional level to provide it with its own governance and funding within the Marqués de Valdecilla Research Institute Foundation (IDIVAL).
Cohorte Cantabria was launched in April 2021 and is led by the Valdecilla Research Institute (IDIVAL). It takes place at the Marqués de Valdecilla University Hospital (HUMV), where staff from IDIVAL and the Cantabrian Health Service work together to ensure excellent care for volunteers on a daily basis.
In a continuing effort to enrich the project, Cohorte Cantabria has recently added a new questionnaire on medical diagnoses covering all specialties. Work is also underway to include cognitive tests and more questionnaires on lifestyle habits to provide an even more complete picture of the determinants of health.
The collaboration of Cantabrians with the study goes beyond the donation of data and samples. Groups such as the Loredo Neighborhood Council, the Aras-Voto Women’s Association and the College of Economists have supported this research with financial contributions since its inception. In addition, companies such as PITMA, Nestlé or Sidenor have already signed an agreement for the dissemination of the study among their workers, facilitating their attendance during working hours. And more and more institutions are approaching the project to initiate scientific collaborations and position Cantabria at the forefront of research.
Cohorte Cantabria aims to recruit 20% of the target population, made up of Cantabrian residents between 40 and 69 years of age. The participation target has already been exceeded in municipalities such as Santa Cruz de Bezana and Camargo, and the team is focusing its efforts on increasing participation in more distant regions such as Liébana, Saja-Nansa, Campoo-Los Valles, Valles Pasiegos and Asón-Agüera to ensure a representative sample of the entire region.
Precision Medicine as a goal
Promoted by IDIVAL, the Valdecilla Hospital and with the support of the Government of Cantabria and the Cantabrian Health Service (SCS), Cohorte Cantabria’s mission is to advance personalized medicine. The study seeks to improve medicine so that it becomes more inclusive and takes a more preventive and predictive approach, protecting the health of all to avoid the development of certain diseases or improve the course of others.
The project, multipurpose and open to the scientific community, is generating an invaluable database with information on the habits, socioeconomic, demographic and clinical factors of the Cantabrian population. This anonymized information is available to develop national and international research projects that address health and disease from multiple perspectives.
For more information or to register, interested parties can visit the project website at https://cohortecantabria.com/.
Photo: part of the Cohort Cantabria team with the 40,000th participant and her husband.
Cantabria’s largest biomedical research project, a pioneer in Spain, makes steady progress towards its goal of 50,000 participants. The ambitious biomedical research project Cohorte Cantabria has today reached 40,000 participants, approaching its goal of 50,000 volunteers. The great reception of this initiative by the Cantabrian population reflects the commitment of our citizens to improve public […]
Researchers from the Immunopathology Group of IDIVAL, led by Dr. Javier Loricera García and Dr. Ricardo Blanco Alonso, have carried out two studies to increase our knowledge of the complications derived from GCA. The first of them arises from the concern generated by the considerable proportion of patients with CGA who relapse despite conventional treatment with high-dose glucocorticoids, methotrexate and/or tocilizumab. The janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is implicated in the pathogenesis of GCA, so inhibitors of janus kinases (iJAK) may constitute a therapeutic alternative.
In the study, the effectiveness of iJAKs in refractory or recurrent GCA in clinical practice is evaluated and, in addition, a review of the literature in this regard is performed.
Analyzing 35 patients from thirteen Spanish hospitals and the Massachusetts General Hospital in Boston (USA), clinical remission, complete remission and safety are evaluated.
The results suggest that iJAKs could be effective in GCA, even in cases refractory to tocilizumab or methotrexate. Pending publication of the results of the randomized controlled clinical trial phase 3 of upadacitinib (NCT03725202), this study may help in making therapeutic decisions in patients with refractory/recurrent GCA.
The article has been published in the prestigious journal Arthritis Research and Therapy.
The second study stems from the need to test the effectiveness of tocilizumab in combating aortitis in GCA, which frequently leads to the formation of aneurysms.
A multicenter retrospective analysis of patients with aortitis secondary to GCA treated with tocilizumab from 57 Spanish hospitals was performed. Remission is evaluated according to the definition of the European Alliance of Rheumatology Associations (EULAR) and by imaging techniques. Clinical remission and normalization of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), the glucocorticoid-sparing effect, as well as the prevention and improvement of aneurysms are also measured.
From a sample of 196 patients, analyzed over two years, results suggest that patients with aortitis in the context of GCA treated with tocilizumab experience rapid and sustained clinical and laboratory improvement. However, this clinical and analytical improvement in many cases does not translate into an improvement in imaging tests. On the other hand, tocilizumab appears to prevent the development of new aneurysms in patients with GCA, but does not appear to prevent the progression of established aneurysms.
The results of that study are shown in the European Journal of Internal Medicine.
References:
Loricera J, Tofade T, Prieto-Peña D, Romero-Yuste S, de Miguel E, Riveros-Frutos A, Ferraz-Amaro I, Labrador E, Maiz O, Becerra E, Narváez J, Galíndez-Agirregoikoa E, González-Fernández I, Urruticoechea-Arana A, Ramos-Calvo Á, López-Gutiérrez F, Castañeda S, ºUnizony S, Blanco R. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. 2024 Jun 5;26(1):116. doi: 10.1186/s13075-024-03314-9. PMID: 38840219; PMCID: PMC11151571.
Martín-Gutiérrez A, Loricera J, Narváez J, Aldasoro V, Maiz O, Vela P, Romero-Yuste S, de Miguel E, Galíndez-Agirregoikoa E, Fernández-López JC, Ferraz-Amaro I, Sánchez-Martín J, Moya P, Campos C, López-Gutiérrez F, Castañeda S, Blanco R; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis. Eur J Intern Med. 2024 Jun 21:S0953-6205(24)00253-X. doi: 10.1016/j.ejim.2024.06.013. Epub ahead of print. PMID: 38908981.
Two new publications show results on the effectiveness of inhibitors of janus kinases (iJAK) in giant cell arteritis (GCA) and on the effectiveness of the antibody tocilizumab for aortitis in GCA. Researchers from the Immunopathology Group of IDIVAL, led by Dr. Javier Loricera García and Dr. Ricardo Blanco Alonso, have carried out two studies to […]
On July 2, the Nursing research group of the Marqués de Valdecilla Health Research Institute (IDIVAL), led by Dr. Carmen Sarabia Cobo, held a progress meeting of the European project JACARDI (Joint Action on Cardiovascular Diseases and Diabetes). This meeting, held at the IDIVAL facilities, highlighted the achievements and outlined the next steps for the co-creation and implementation of three pilots in Cantabria.
The Joint Action on Cardiovascular Diseases and Diabetes (JACARDI) aims to reduce the burden of these diseases in the countries of the European Union, both at the individual and societal levels. The project seeks to integrate validated best practices and/or cost-effective interventions in different countries and regions through transnational pilot initiatives. These activities complement and reinforce existing policies and programs, covering the entire patient journey, from health literacy and awareness, to primary prevention and improved care pathways and self-management.
JACARDI also addresses cross-cutting and intersectional issues, such as promoting health equity, social, cultural and ethnic diversity, and improving data availability. With the participation of 21 EU countries and 76 partners, JACARDI will implement 142 pilots ensuring a wide geographical coverage. The adoption of a common implementation and evaluation methodology will facilitate the analysis of success factors and context, with the aim of scaling up experiences at national and regional level.
In addition, the project will also include the co-creation of a roadmap to extend the impact beyond the culmination of this 4-year project. With these initiatives, IDIVAL’s Nursing research group is committed to improving the health and well-being of patients in Cantabria, contributing significantly to the objectives of the European joint action project JACARDI.
The meeting of the IDIVAL Nursing research group highlighted the progress and next steps in the pilots it is leading in Cantabria on health literacy, integrated care pathways and self-management of patients with these diseases. On July 2, the Nursing research group of the Marqués de Valdecilla Health Research Institute (IDIVAL), led by Dr. Carmen […]
The Valdecilla Clinical Trials Unit and the Research Support Unit of the Marqués de Valdecilla Research Institute (IDIVAL) have highlighted the importance of specialised talent in supporting the execution of clinical trials. This announcement comes in light of recent findings published in a comprehensive review on challenges and solutions in the field of clinical trials.
The study, entitled ‘Navigating the challenges of clinical trial professionals in the healthcare sector’ and published in Frontiers in Medicine, reveals that the complexity and evolving nature of clinical trials requires specialised and ongoing training for the professionals involved. These professionals include principal investigators, clinical research coordinators (CRCs), nurses, clinical trial pharmacists and monitors, each facing unique challenges such as maintaining protocol compliance, managing investigational products and ensuring data integrity.
The publication emphasises that addressing these challenges requires clear role delineation, continuous professional development and supportive work environments to improve staff retention and trial outcomes. Enhanced training programmes and a collaborative approach are essential for the successful conduct of clinical trials and the advancement of medical research.
Blanca Sánchez-Santiago, co-author of the study and member of the Clinical Pharmacology Service of the Clinical Trials Unit at the Marqués de Valdecilla University Hospital, added: ‘It is crucial to invest in competence development and clear role definition within clinical trial teams to ensure data integrity and participant well-being’.
The article also highlights the need for adequate support systems that are characterised by a highly demanding organisational framework, based on the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. This guideline sets the international standard for ethical and scientific quality in the design, conduct and reporting of clinical trials, protecting the rights, safety and well-being of trial participants.
The Valdecilla Clinical Trials Unit and the IDIVAL Research Support Unit continue to lead efforts to improve training and support for clinical trial professionals, recognising that talent and training are fundamental to the success and quality of clinical research.
Reference:
The Valdecilla Clinical Trials Unit and the Research Support Unit of the Marqués de Valdecilla Research Institute (IDIVAL) have highlighted the importance of specialised talent in supporting the execution of clinical trials. This announcement comes in light of recent findings published in a comprehensive review on challenges and solutions in the field of clinical trials. […]
Next Wednesday, June 5, Dr. Young J. Juhn will visit IDIVAL with the aim of establishing a collaboration with Cohorte Cantabria.
Dr. Young J. Juhn is Professor of Pediatrics and Clinical Investigator at the Mayo Clinic. He is currently the Chair of Research at Mayo Clinic Health System and Director of the Artificial Intelligence Program in the Department of Pediatric and Adolescent Medicine. In addition, he leads the Precision Population Science Lab research group and the HOUSES program. His research focuses on health disparities and the study of bias in artificial intelligence models. Throughout his career, he has published more than 150 research articles and has trained more than 80 researchers.
At 10:30, in IDIVAL’s Sala Grande, Dr. Juhn will give a talk open to the public entitled “THE HOUSES PLATFORM: Groundbreaking Social Determinants of Health Metric & A Digital Biomarker in Clinical and Translational Science”. The HOUSES index, developed by Dr. Juhn and his team at the Mayo Clinic, provides an individual measure of socioeconomic status based on housing characteristics, allowing analysis of how social determinants can impact health. Its implementation has been key in the United States to support health research and public policy aimed at determining the mechanisms underlying disparities in access to the healthcare system.
That same day, the Cohort Cantabria team and collaborators will meet with Dr. Juhn to advance a future collaboration between both institutions focused on the use of the data collected in Cohort Cantabria for the validation of the HOUSES index in a European population sample. This will allow a deeper analysis of the social determinants that may affect health in our region.
Next Wednesday, June 5, Dr. Young J. Juhn will visit IDIVAL with the aim of establishing a collaboration with Cohorte Cantabria. Dr. Young J. Juhn is Professor of Pediatrics and Clinical Investigator at the Mayo Clinic. He is currently the Chair of Research at Mayo Clinic Health System and Director of the Artificial Intelligence Program […]
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment
Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as well as entailing large economic costs.
The III Northern Headache Meeting will start next Friday 7th June, a two-day conference with expert speakers in the field of headaches who will discuss the latest advances in their diagnosis and treatment.
The meeting is organised by Julio Pascual and Vicente González, researchers from the Clinical and Genetic Group of Headaches at the Marqués de Valdecilla Health Research Institute (IDIVAL) and neurologists from the Marqués de Valdecilla University Hospital (HUMV) and is sponsored by Lundbeck, Pfizer, Almirall, abbvie, Teva and Lilly-Organon.
The conference will take place at the Hotel Santemar in Santander and registration can be done through the following link: https://forms.gle/kWNyBDqaz2ataFTu5
In the first session, after the opening and welcome by the organisers, there will be a round table discussion entitled “Not everything is migraine” in which researchers Gabriel Gárate and Jorge Madera will discuss the biomarkers that currently exist to diagnose migraine, as well as the different types of headaches and how to differentiate them.
This will be followed by a competition of clinical cases presented by people who are doing their residency in medicine (MIR) in the speciality of neurology and the last year of their internship in hospitals in Castilla y León, Asturias, the Basque Country, Navarre, La Rioja or Cantabria. Cases may be submitted until 30 May to the following address: v.glezquintanilla@gmail.com.
For the selection of the winning case, on the one hand, the evaluation by the Scientific Committee will take into account aspects such as the description, the systematics of the diagnosis, the review of the literature, the interest and the innovation. On the other hand, the participants will have to present their case orally and those attending the conference will be able to score them. Finally, the average of the scores of the jury and the audience will be calculated and the winner will receive a prize. In addition, those clinical cases with a score of at least 5 out of 10 will be collected in a digital book with ISBN.
The second session of the conference, on 8 June, will consist of two round tables focusing on the field of migraine, such as the current treatment of symptoms and new drugs under study such as monoclonal antibodies or new oral gepants. Finally, the indications and controversies of neuroimaging techniques in headaches will be discussed and there will be a final colloquium on the future of a headache consultation.
You can download the programme with detailed rules for participating in the clinical case competition here:
Programme III Northern Headache Meeting 2024 and clinical cases
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as […]
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment
Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as well as entailing large economic costs.
The III Northern Headache Meeting will start next Friday 7th June, a two-day conference with expert speakers in the field of headaches who will discuss the latest advances in their diagnosis and treatment.
The meeting is organised by Julio Pascual and Vicente González, researchers from the Clinical and Genetic Group of Headaches at the Marqués de Valdecilla Health Research Institute (IDIVAL) and neurologists from the Marqués de Valdecilla University Hospital (HUMV) and is sponsored by Lundbeck, Pfizer, Almirall, abbvie, Teva and Lilly-Organon.
The conference will take place at the Hotel Santemar in Santander and registration can be done through the following link: https://forms.gle/kWNyBDqaz2ataFTu5
In the first session, after the opening and welcome by the organisers, there will be a round table discussion entitled “Not everything is migraine” in which researchers Gabriel Gárate and Jorge Madera will discuss the biomarkers that currently exist to diagnose migraine, as well as the different types of headaches and how to differentiate them.
This will be followed by a competition of clinical cases presented by people who are doing their residency in medicine (MIR) in the speciality of neurology and the last year of their internship in hospitals in Castilla y León, Asturias, the Basque Country, Navarre, La Rioja or Cantabria. Cases may be submitted until 30 May to the following address: v.glezquintanilla@gmail.com.
For the selection of the winning case, on the one hand, the evaluation by the Scientific Committee will take into account aspects such as the description, the systematics of the diagnosis, the review of the literature, the interest and the innovation. On the other hand, the participants will have to present their case orally and those attending the conference will be able to score them. Finally, the average of the scores of the jury and the audience will be calculated and the winner will receive a prize. In addition, those clinical cases with a score of at least 5 out of 10 will be collected in a digital book with ISBN.
The second session of the conference, on 8 June, will consist of two round tables focusing on the field of migraine, such as the current treatment of symptoms and new drugs under study such as monoclonal antibodies or new oral gepants. Finally, the indications and controversies of neuroimaging techniques in headaches will be discussed and there will be a final colloquium on the future of a headache consultation.
You can download the programme with detailed rules for participating in the clinical case competition here:
Programme III Northern Headache Meeting 2024 and clinical cases
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as […]
Cohorte IMPaCT is an ambitious health study of the Instituto de Salud Carlos III coordinated by the Centro de Investigación Biomédica en Red (CIBER) that aims to monitor the health of 200,000 people living in Spain over 20 years.
Cohorte IMPaCT is being developed thanks to the participation of all the Autonomous Communities. It will be carried out in 50 primary care health centers (IMPaCT Centers) belonging to the health services of the 17 Autonomous Communities and Ceuta and Melilla, where recruitment, information collection and periodic contact with the participants will be carried out.
IMPaCT Cohort in Cantabria
One of these 50 IMPaCT Centers will be located in Cantabria. The Puertochico Health Center, where the IMPaCT Center is located, has a multidisciplinary team made up of researchers and healthcare professionals from the Cantabrian Health Service. Users of the Puertochico Health Center, CS Isabel II and CS Dávila of Santander will be called from this Health Center.
In Cantabria, the IMPaCT Cohort is managed by the Valdecilla Research Institute (IDIVAL) and the Cantabrian Health Service, through the Primary Care Management, coordinates and executes the study in the Puertochico Health Center (Santander) as the project node. Cohorte IMPaCT is coordinated in Cantabria by Luis Mariano López López, Director of Nursing at the Marqués de Valdecilla University Hospital, and Álvaro Ramos Acosta, Deputy Director of Nursing at the Marqués de Valdecilla University Hospital.
A representative sample of the Spanish population
The IMPaCT Cohort has been designed so that its 200,000 participants are a representative sample of the Spanish population. Territorially, there are IMPaCT Centers in all the Autonomous Communities and in Ceuta and Melilla. In line with the distribution of the Spanish population, 30% of these centers will be in rural areas and another 70% in urban areas.
A person cannot volunteer to participate in the IMPaCT Cohort. To ensure a faithful representation of the Spanish population, participants are chosen at random. Persons aged 16 to 79 years living in Spain with public health coverage and whose care is provided by Public Health Service centers will be eligible.
Cohorte IMPaCT will mark the history of science in our country: a project of everyone and for everyone that will allow us to better understand why some people get sick and others do not. This project will help us to improve the health of future generations in Spain.
People who have been selected will receive a text message telling them that they will be contacted from their Health Center to participate in the study, as well as a link to the project’s informative website. The involvement of the citizens who are called to participate is key to the success of the project, which is why its slogan is: “If they call you, come!
Video presentation of IMPaCT Cohort in Cantabria:
IMPaCT Cohort Web Page
Cohorte IMPaCT is an ambitious health study of the Instituto de Salud Carlos III coordinated by the Centro de Investigación Biomédica en Red (CIBER) that aims to monitor the health of 200,000 people living in Spain over 20 years. Cohorte IMPaCT is being developed thanks to the participation of all the Autonomous Communities. It will […]
